Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.35 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15298140 | 0.99 | STK17B (0.45) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL25955381 | 0.85 | STK17B (0.41) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL2723184 | 0.85 | STK17B (0.41) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL18638035 | 0.84 | STK17B (0.42) | STK17BSTK17AP2RX7SYKMAPKAPK2 | |
| SCHEMBL29437376 | 0.84 | STK17B (0.41) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL2724824 | 0.84 | STK17B (0.41) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL20980140 | 0.84 | STK17B (0.47) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL20926997 | 0.84 | STK17B (0.47) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL2724465 | 0.84 | STK17B (0.47) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL2726118 | 0.82 | STK17B (0.48) | STK17BSTK17AP2RX7NPFFR1NPFFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632467-B1 | CDK INHIBITORS | G1 THERAPEUTICS INC (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2955183-A1 | CDK INHIBITORS | G1 Therapeutics, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014144740-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144847-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144326-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |